Compare Eni SpA (E) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Organon & Co. Common Stock — how do they compare? Eni SpA trades at $58.97 (market cap $82.04B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Eni SpA is far larger — about 22.7× Organon & Co. Common Stock's market cap, and Eni SpA pays the higher dividend (4.25%). Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Organon & Co. Common Stock for 0 Days on average.
| E | OGN | |
|---|---|---|
Market Cap | $82.04B | $3.62B |
Volume | 245,093 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $57.71 | $13.81 |
52-Week Low | $34.20 | $5.70 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $106.48B | $11.04B |
Dividend Yield | 4.25% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $57.71, up 1.66% today, with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 13.35 and P/S of 0.88, though recent earnings missed expectations in Q1 and Q2 2026. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, but net income margin improved to 5.97% in 2026 projections. Recent developments include expansion in Venezuela oil opportunities and humanoid robotics partnerships.
The outlook remains cautiously optimistic with 34.6% analyst buy ratings and improving profitability margins. Key opportunities include Venezuela oil expansion and cost discipline, while risks involve revenue volatility and execution challenges. The stock presents value characteristics with reasonable valuation, though investors should monitor earnings consistency and global energy market conditions.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
